HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

clebopride

antidopaminergic; RN given refers to parent cpd; structure
Also Known As:
N-1-benzyl-4 piperidil-3-methoxy-4-amino-5-chlorobenzamide; clebopride fumarate (1:1); clebopride maleate; clebopride maleate (1:1); clebopride mono-hydrochloride; cleboril; N-(1'-benzyl-4'-piperidyl)-2-methoxy-4-amino-5- chlorobenzamide
Networked: 36 relevant articles (3 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Allocca, R: 1 article (06/2012)
2. Santangelo, G: 1 article (06/2012)
3. Erro, R: 1 article (06/2012)
4. Amboni, M: 1 article (06/2012)
5. Barone, P: 1 article (06/2012)
6. Vitale, C: 1 article (06/2012)
7. Berriozabal Diaz, L: 1 article (03/2011)
8. Zapata Morcillo, E: 1 article (03/2011)
9. Zubiaurre Lizarralde, L: 1 article (03/2011)
10. Castiella Eguzkiza, A: 1 article (03/2011)

Related Diseases

1. Vomiting
2. Dyspepsia (Indigestion)
3. Nausea
4. Catalepsy
12/01/1996 - "Administration of the D1 antagonist SCH 23390 (0.2 or 1.0 mg/kg) or the D2 antagonist clebopride (1.0, 10.0, or 20.0 mg/kg) led to catalepsy and dorsal immobility in intact rats, regardless of test age. "
11/01/1995 - "However, combined administration of SCH 23390 + clebopride induced similar akinesia, catalepsy, and somatosensory neglect in both controls and DA depleted animals. "
11/07/1994 - "Moreover, since important changes in DA receptor ontogeny occur during the first postnatal week, we compared the ability of the D1-like antagonist, SCH 23390 (0.2 mg/kg), or the D2-like antagonists, clebopride (10.0 mg/kg) and haloperidol (1.0 mg/kg), to induce akinesia or catalepsy in adults depleted of DA on either day 1 or on day 3. Rats depleted of striatal DA (> 95%) at either age exhibited similar subsensitivity to D1 or D2 antagonists. "
11/01/1995 - "The ability of bilateral intrastriatal injections (0.5 microliter) of DA receptor antagonists to induce motoric deficits was determined in adult rats treated with vehicle or 6-OHDA (100 micrograms, intraventricular) on postnatal day 3. Administration of the D1-like antagonist SCH 23390 (0.5-2.0 micrograms) or the D2-like antagonist clebopride (1.0-4.0 micrograms) induced dose-dependent akinesia, catalepsy, and somatosensory neglect in vehicle-treated controls. "
06/11/1993 - "In the present study, we investigated the ability of NMDA receptor antagonists to inhibit catalepsy induced by haloperidol, or SCH23390 and clebopride, selective dopamine D1 and D2 receptor antagonists respectively. "
5. Gastritis

Related Drugs and Biologics

1. Cisapride (Propulsid)
2. Metoclopramide (Reglan)
3. Cisplatin (Platino)
4. Domperidone (Domperidon)
5. SCH 23390
6. Haloperidol (Haldol)
7. Dopamine (Intropin)
8. N-Methylaspartate (NMDA)
9. Cimetidine (Biomet)
10. Dopamine Antagonists

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Gamma Cameras (Gamma Camera)
3. Injections
4. Transcutaneous Electric Nerve Stimulation (TENS)
5. Anesthesia